Korea’s Ministry of Food and Drug Safety (MFDS) is advancing a “full-cycle regulatory system” for rare disease drugs to reduce delays and improve patient access. Rare disease drug development is often hindered by small patient populations and limited clinical data, making trial-and-error particularly costly. Waiting until the final approval stage to address regulatory requirements can result in significant time and financial losses.
As a result, the MFDS has strengthened early intervention through its Regulatory Alignment Review system, which examines applicable regulations, data requirements, and approval strategies for orphan drugs at the research stage. The agency says the goal is to guide sponsors from the beginning and reduce mid-development failures that can stall commercialization.
Policy support continues for rare diseases through later stages. Recent revisions to the Korean Orphan Drug Designation system allow more flexible new designations, even when other products are already designated for the same condition. Once designated, products may qualify for expedited pathways. The Korean GIFT fast-track review system has contributed to increased approvals in areas with limited treatment options, especially in rare diseases and oncology.
Regulatory flexibility has also expanded during review. For therapies addressing high unmet medical needs, priority conditional approval may be granted based on phase 2 data. Thus, confirmatory data may be submitted post-approval.
While initially focused on rare diseases, the MFDS suggests that this model could potentially extend to advanced biopharmaceuticals such as gene and cell therapies.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.